Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: COO

The Cooper Companies, Inc.

Healthcare | Medical - Instruments & Supplies
$74.20 +12.07 (+19.43%) as of 2026-07-15 06:40 UTC
Market Cap$14.5B
Volume2.95M
EPS (TTM)$1.87

The Cooper Companies, Inc. (NASDAQ: COO) is a $14.5B medical - instruments & supplies company trading at $74.20 (+19.4% today) — 39.7× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-15 06:40 UTC.

52-Week Range
Low $61.71High $74.45

What The Cooper Companies, Inc. does

Cooper Companies is a global medical device company operating through two segments: CooperVision and CooperSurgical. CooperVision manufactures and markets contact lenses in various types and materials to address vision challenges like astigmatism and myopia, including the FDA-approved MiSight lens for slowing myopia progression in children. CooperSurgical offers more than 600 products and services for fertility and women's health, used in medical offices, surgical centers, hospitals, and fertility clinics.

Summarized from The Cooper Companies, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$74.20
Change (1D)+12.07 (+19.43%)
Market cap$14.5B
Volume2.95M shares
52-week range$61.71 – $74.45
Valuation
P/E (TTM)39.68×
EV/EBITDA15.90×
EPS (TTM)$1.87
Price/book1.76×
Return on equity4.55%
Debt/equity0.30
Returns
52-week return+20.2%
Revenue, margins & earnings
FY2021 Revenue: $2.92B — margin split not shown (non-operating gains)$2.92BFY2021FY2022 Net income: $386MFY2022 Taxes & interest: $122MFY2022 Operating expenses: $1.63BFY2022 Cost of revenue: $1.17B$3.31BFY2022FY2023 Net income: $294MFY2023 Taxes & interest: $239MFY2023 Operating expenses: $1.82BFY2023 Cost of revenue: $1.24B$3.59BFY2023FY2024 Net income: $392MFY2024 Taxes & interest: $313MFY2024 Operating expenses: $1.89BFY2024 Cost of revenue: $1.30B$3.90BFY2024FY2025 Net income: $375MFY2025 Taxes & interest: $308MFY2025 Operating expenses: $2.00BFY2025 Cost of revenue: $1.41B$4.09BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net income above revenue (non-operating gains)
Annual revenue; bands show net, operating, gross margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-06
  • 2026-07-06Keel Paul AA2,814—
  • 2026-04-21Rosebrough Walter M JrA832—
  • 2026-04-21Rosebrough Walter M JrM832—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC23,456,309$1.92B-2.2%
  • VANGUARD CAPITAL MANAGEMENT LLC12,718,829$909.40MNEW
  • BlackRock, Inc.12,715,648$909.17M-22.9%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does The Cooper Companies, Inc. do?

Cooper Companies is a global medical device company operating through two segments: CooperVision and CooperSurgical.

What is COO's valuation?

COO trades at $74.20, 39.68× trailing earnings, 15.90× EV/EBITDA, as of 2026-07-15.

When did COO last file with the SEC?

The Cooper Companies, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-06-05. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 06:40 UTC. This page is also available as JSON at /api/data?ticker=COO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for COO and 3,500+ tickers.

Create a free account — keep COO
For your agent
GET /api/data?ticker=COO

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt